2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American …
Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …
Autoimmune myocarditis, old dogs and new tricks
Autoimmunity significantly contributes to the pathogenesis of myocarditis, underscored by its
increased frequency in autoimmune diseases such as systemic lupus erythematosus and …
increased frequency in autoimmune diseases such as systemic lupus erythematosus and …
[HTML][HTML] Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study
N Vinter, P Cordsen, SP Johnsen, L Staerk… - bmj, 2024 - bmj.com
Objectives To examine how the lifetime risks of atrial fibrillation and of complications after
atrial fibrillation changed over time. Design Danish, nationwide, population based cohort …
atrial fibrillation changed over time. Design Danish, nationwide, population based cohort …
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology …
The 2021 Update to the 2017 American College of Cardiology (ACC) Expert Consensus
Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues …
Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues …
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the …
Abstract Aim The “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS
Guideline for the Management of Lower Extremity Peripheral Artery Disease” provides …
Guideline for the Management of Lower Extremity Peripheral Artery Disease” provides …
Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference
Aims Recent trial data demonstrate beneficial effects of active rhythm management in
patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is …
patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is …
Pathophysiology and clinical relevance of atrial myopathy
MRL Tubeeckx, GW De Keulenaer… - Basic Research in …, 2024 - Springer
Atrial myopathy is a condition that consists of electrical, structural, contractile, and autonomic
remodeling of the atria and is the substrate for development of atrial fibrillation, the most …
remodeling of the atria and is the substrate for development of atrial fibrillation, the most …
Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban
Importance Diltiazem, a commonly prescribed ventricular rate–control medication for
patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly …
patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly …
Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper
T Potpara, M Grygier, KG Haeusler… - Europace, 2024 - academic.oup.com
A significant proportion of patients who suffer from atrial fibrillation (AF) and are in need of
thromboembolic protection are not treated with oral anticoagulation or discontinue this …
thromboembolic protection are not treated with oral anticoagulation or discontinue this …
[HTML][HTML] Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA …
Atrial fibrillation (AF) may be asymptomatic and the extensive monitoring capabilities of
cardiac implantable electronic devices (CIEDs) revealed asymptomatic atrial tachi …
cardiac implantable electronic devices (CIEDs) revealed asymptomatic atrial tachi …